Endo International Monday reported it launched Natesto, which it described as the market’s first nasal gel for testosterone-replacement therapy in adult males diagnosed with hypogonadism, or lack of testosterone.
Endo noted the nasal gel was approved by the Food and Drug Administration in May 2014 for adult men with deficiency or absence of endogenous testosterone, including conditions both congenital or acquired.
Endo also makes and sells other testosterone gels and implantable testosterone pellets, but it said the nasal gel reduces the risk of transference via intranasal application.
The company said it obtained rights to the nasal gel for sale in the U.S. and Mexico from Trimel Pharmaceuticals for $25 million, plus additional payments related to regulatory and sales milestones. ENDP was up 0.9% in recent pre-market trading at $88.11, in a 52-week range of $53.62 to $92.80.